View this email in your browser
This month in CAR-T research

Welcome to the CAR-T Grease Monkeys newsletter #4. Now with more puns. Here's what new on the (clinical) race track, the (academic) garage and in the shop this September.

Happy reading, 

News from the race track

1. Phase I: Less passionate CAR-Ts stick around longer and doesn't give you a headache:
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Nat Med. 2019 Sep.

2. Case series: Delhi belly following CAR treatment:
Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy.
Am J Clin Oncol. 2019 Oct.

3. Not easy to see: imaging the brain after CAR-T treatments
Chimeric Antigen Receptor T-Cell Neurotoxicity Neuroimaging: More Than Meets the Eye.
AJNR Am J Neuroradiol. 2019 Sep 5.

4. Case report: anti-CD19 CAR effective against refractory Waldenström macroglobulinemia.
Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia.
Leuk Lymphoma. 2019 Sep 22.

News from the garage

5. Coupling anti-CD70 CARs to a IL-8 receptor increases intratumour migration
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Nat Commun. 2019 Sep 5.

6. What makes CARs go? Leveraging signaling pathways affected during expansion for better on-target CARs:
Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.
Sci Signal. 2019 Sep 10.

7. CARdiac T-cells cure a troubled heart:
Targeting cardiac fibrosis with engineered T cells.
Nature. 2019 Sep.

8. BAFFeR CAR-Ts to avoid antigen loss:
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.
Sci Transl Med. 2019 Sep 25.

9. CAR-T's go for the liver (without the fava beans):
Eradication of hepatocellular carcinoma by NKG2D-specific CAR T-cells.
Cancer Immunol Res. 2019 Sep 4.

10. GD2-specific iNKT CARs expressing IL-15 fight neuroblastoma:
NKT cells co-expressing a GD2-specific chimeric antigen receptor and IL-15 show enhanced in vivo persistence and antitumor activity against neuroblastoma.
Clin Cancer Res. 2019 Sep 4.

11. IgniTIGITion of CAR-Ts:
A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
J Immunother Cancer. 2019 Sep 9.

12. Exhaust from CAR-Ts apparently beneficial:
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity.
Nat Commun. 2019 Sep 25.

13. Triple-reactive CARs using DARPins:
Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors.
Clin Cancer Res. 2019 Sep 23.

14. Who wore it better?
Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.
Sci Rep. 2019 Sep 16.

15. Getting the target to stick: inhibiting BCMA from leaving cancer cells:
γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Blood. 2019 Sep 26.

16. PD1-TIM3-LAG3 knockout enhances CARs in mouse model:
Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56.
Nat Commun. 2019 Sep 11.

17. CAR macrophages not fast enough to keep up with cancer cells:
Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix.
Br J Cancer. 2019 Oct 1.

Overheard at the shop

18. What have we learned? Whats next?
Clinical lessons learned from the first leg of the CAR T cell journey.
Nat Med. 2019 Sep.

19. Fueling the CAR: how to enhance CAR-T metabolism.
Metabolic Consequences of T-cell Costimulation in Anticancer Immunity
Cancer Immunol Res. 2019 Oct.

CARs elsewhere

20. Conference report: ACIR goes to CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.

21. Conference report: SITC goes to ESMO.
Our mailing address is:
Departement of clinical
OUH, J.B. Winsløws vej 4
Odense 5000

Add us to your address book

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Departement of clinical · OUH, J.B. Winsløws vej 4 · Odense 5000 · Denmark

Email Marketing Powered by Mailchimp